Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NCI Phase III Trial On Shark Cartilage May Begin Recruitment Summer/Fall

This article was originally published in The Tan Sheet

Executive Summary

A National Cancer Institute Phase III trial on the effects of shark cartilage on stages 3a and 3b inoperable non-small cell lung cancer may begin recruitment in the late summer or early fall.

You may also be interested in...



Lane Labs FTC Settlement To Fund National Cancer Institute Study

Lane Labs has been ordered by the Federal Trade Commission to contribute $450,000 to fund a National Cancer Institute clinical study on the effects of shark cartilage supplementation on cancer as part of a $1 mil. settlement of charges it made unsubstantiated cancer claims for its dietary supplements.

Lane Labs FTC Settlement To Fund National Cancer Institute Study

Lane Labs has been ordered by the Federal Trade Commission to contribute $450,000 to fund a National Cancer Institute clinical study on the effects of shark cartilage supplementation on cancer as part of a $1 mil. settlement of charges it made unsubstantiated cancer claims for its dietary supplements.

Lane Labs FTC Settlement To Fund National Cancer Institute Study

Lane Labs has been ordered by the Federal Trade Commission to contribute $450,000 to fund a National Cancer Institute clinical study on the effects of shark cartilage supplementation on cancer as part of a $1 mil. settlement of charges it made unsubstantiated cancer claims for its dietary supplements.

Related Content

Topics

UsernamePublicRestriction

Register

PS089476

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel